Tasaki, Shinya
Suzuki, Katsuya
Kassai, Yoshiaki
Takeshita, Masaru
Murota, Atsuko
Kondo, Yasushi
Ando, Tatsuya
Nakayama, Yusuke
Okuzono, Yuumi
Takiguchi, Maiko
Kurisu, Rina
Miyazaki, Takahiro
Yoshimoto, Keiko
Yasuoka, Hidekata
Yamaoka, Kunihiro
Morita, Rimpei
Yoshimura, Akihiko
Toyoshiba, Hiroyoshi
Takeuchi, Tsutomu
Article History
Received: 25 October 2017
Accepted: 8 June 2018
First Online: 16 July 2018
Competing interests
: S.T., Y.N., T.M. and H.T. were employed by Takeda Pharmaceutical Company Limited. Yo.K., T.A., Y.O., Mai.T. and R.K. are employed by Takeda Pharmaceutical Company Limited. Y.N. is employed by ONO Pharmaceutical. T.M. is employed by Nektar Therapeutics. H.T. is employed by FRONTEO. K.S. has received research grants from Eisai, Bristol-Myers Squibb, Kissei Pharmaceutical, and Daiichi Sankyo, and speaking fees from Abbie Japan, Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Fuji Film Limited, Janssen Pharmaceutical, Kissei Pharmaceutical, Mitsubishi Tanabe Pharmaceutical, Pfizer Japan, Shionogi, Takeda Pharmaceutical, and UCB Japan, consulting fees from Abbie, and Pfizer Japan. A.Y. has received speaking fees from Chugai Pharmaceutical, Mitsubishi Tanabe Pharmaceutical, Pfizer Japan, Ono Pharmaceutical, Maruho, and Novartis, and consulting fees from GSK Japan. Ku.Y. has received consultant fees from Pfizer, Chugai Pharma, Mitsubishi Tanabe Pharma, Abbvie, received honoraria from Pfizer, Chugai Pharma, Mitsubishi Tanabe Pharma, Bristol-Myers Squibb, Takeda Industrial Pharma, GlaxoSmithkline, Nippon Shinyaku, Eli lilly, Janssen Pharma, Eisai Pharma, Astellas Pharma, Actelion Pharmaceuticals and received research grants from Chugai Pharma, Mitsubishi Tanabe Pharma., and Glaxo Smith Kline. H.Y. has received research grants from Daiichi Sankyo, Takeda Pharmaceutical, Eisai, and Japan Blood Products Organization, and speaking fees from Abbie Japan, Bristol-Myers Squibb, Takeda Pharmaceutical, Chugai Pharmaceutical, and Eisai. T.T. has received research grants from Astellas Pharma Inc, Bristol-Myers K.K., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd., AbbVie GK, Asahikasei Pharma Corp., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., and Taisho Toyama Pharmaceutical Co. Ltd., Eisai Co. Ltd., AYUMI Pharmaceutical Corporation, and Nipponkayaku Co. Ltd, and speaking fees from AbbVie GK., Bristol-Myers K.K., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., and Astellas Pharma Inc., and Diaichi Sankyo Co. Ltd., and consultant fees from Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., Mitsubishi Tanabe Pharma Co., Abbivie GK, Nipponkayaku Co. Ltd, Janssen Pharmaceutical K.K., Astellas Pharma Inc., and Taiho Pharmaceutical Co. Ltd. The remaining authors declare no competing interests.